Re: Farmas USA
NVIV
Y que no tienen pasta...
Acabo de mirarme la última presentación:
Market Cap $214.55 M (a 23-9-2016)
Primary Shares Outstanding 31.9 M (a 28-7-2016)
Fully Diluted Shares 38.5 M
Cash on Hand $41.6 M (a 30-6-2016)
Monthly cash burn of about $1.3 M
The INSPIRE Study
–
Study Design: 20 pacientes
• Primary Objective: To evaluate whether the Scaffold is safe and demonstrates probable benefit for the treatment of AIS A T2-T12/L1 spinal cord injury (within 96 hrs of injury)
• Primary Endpoint: AIS conversion by 6 month follow-up visit
• Objective Performance Criterion:At least 25% of subjects convert from complete paraplegia (AIS A) to partial paralysis by 6 months
Large, multinational, natural history databases consistently indicate that only 12-16% of subjects with complete (AIS A) thoracic injury will convert to an improved AIS grade within 6 months after injury
• Additional Endpoints: Sensory and motor scores, bladder and bowel function, Spinal Cord Independence Measure, pain, quality of life
– Pioneering Spinal Cord Injury Therapies
•
Two Ground-Breaking Investigational Products for Spinal Cord Injury (SCI)
–
Acute SCI: Neuro-Spinal Scaffold™ implant (in pivotal study)
–
Chronic SCI: Bioengineered Neural Trails™ injection (research stage)
•No Treatments Available for SCI
•Pivotal Study Underway for Neuro-Spinal Scaffold–FDA filing for approval expected 2017
•Compelling Early Data for Neuro-Spinal Scaffold
–5 of 8 study patients in follow up (62.5%) have regained neurologic function
versus historical benchmark of 15%
La sorpresa son dos pacientes pediátricos. La capacidad de recuperación es mayor.
«Después de nada, o después de todo/ supe que todo no era más que nada.»